Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (17)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Pettitt, D.
Right arrow Articles by Maniadakis, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pettitt, D.
Right arrow Articles by Maniadakis, N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2000; 39: 33-42
© 2000 British Society for Rheumatology

SUPPLEMENT

Overview of the Arthritis Cost Consequence Evaluation System (ACCES)

a pharmacoeconomic model for celecoxib

D. Pettitt, J. L. Goldstein1, A. McGuire2, J. S. Schwartz3, T. Burke4 and N. Maniadakis5,6

Outcomes Research, Pfizer Inc, New York, NY
1 Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA
2 Department of Economics, City University, Northampton Square, London, UK
3 School of Medicine and The Wharton School, University of Pennsylvania, Philadelphia, PA
4 Global Health Outcomes/ North America, Pharmacia Corporation, Skokie, IL, USA
5 Global Health Outcomes/ Europe, Pharmacia Corporation, High Wycombe, Bucks, UK
6 Present address: European Health Outcomes Research, Eli Lilly and Company Limited, Lilly Research Centre, Erl Wood Manor, Sunninghill Road, Windlesham, Surrey GU206PH, UK

Correspondence to: Correspondence to: D. Pettitt, Outcomes Research, Pfizer Inc, New York, NY, USA.

Abstract

Pharmacoeconomic analyses have become useful and essential tools for health care decision makers who increasingly require such analyses prior to placing a drug on a national, regional or hospital formulary. Previous health economic models of non-steroidal anti-inflammatory drugs (NSAIDs) have been restricted to evaluating a narrow range of agents within specific health care delivery systems using medical information derived from homogeneous clinical trial data. This paper summarizes the Arthritis Cost Consequence Evaluation System (ACCES)—a pharmacoeconomic model that has been developed to predict and evaluate the costs and consequences associated with the use of celecoxib in patients with arthritis, compared with other NSAIDs and NSAIDs plus gastroprotective agents. The advantage of this model is that it can be customized to reflect local practice patterns, resource utilization and costs, as well as provide context-specific health economic information to a variety of providers and/or decision makers.

KEY WORDS: NSAIDs, COX-2 inhibitors, GI discomfort, Health outcomes, Pharmacoeconomic model


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.